Sugi Predict

Sugi Predict / Compounds / SCHEMBL359039

SCHEMBL359039

SCHEMBL359039

COc1cc2[nH]ncc2cc1N

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 1/20 0.65
▸ CHEK1 O14757 1/20 0.63
▸ MKNK1 Q9BUB5 5/20 0.52
▸ TLR8 Q9NR97 1/20 0.51
▸ TRPA1 O75762 1/20 0.49
▸ TRPM8 Q7Z2W7 1/20 0.49
▸ KDM4E B2RXH2 3/20 0.46
▸ GAA P10253 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ PKM P14618 2/20 0.46
▸ HTT P42858 1/20 0.46
▸ ROCK2 O75116 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ ROCK1 Q13464 1/20 0.46
▸ HIF1A Q16665 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30153817 1.00 AXL (0.65) AXLCHEK1MKNK1TLR8TRPA1
SCHEMBL27227850 0.93 CHEK1 (0.63) AXLCHEK1MKNK1TLR8TRPA1
SCHEMBL3560175 0.85 AXL (0.73) AXLCHEK1MKNK1TLR8TRPA1
SCHEMBL30703666 0.81 CHEK1 (0.58) AXLCHEK1MKNK1TLR8TRPA1
SCHEMBL15534402 0.81 CHEK1 (0.58) AXLCHEK1MKNK1TLR8TRPA1
SCHEMBL15536254 0.81 CHEK1 (0.58) AXLCHEK1MKNK1TLR8TRPA1
SCHEMBL20617830 0.80 AXL (0.67) AXLCHEK1MKNK1TLR8TRPA1
SCHEMBL15533837 0.79 CHEK1 (0.54) AXLCHEK1MKNK1TLR8TRPA1
SCHEMBL24358770 0.79 AXL (0.65) AXLCHEK1MKNK1TLR8TRPA1
SCHEMBL1541999 0.79 AXL (0.65) AXLCHEK1MKNK1TLR8TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4310080-A1 POLYMORPHIC FORMS OF COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Meiyue Biotech Development Co., Ltd. (CN) 2024-01-24 — — EP disclosed
EP-3647311-B1 RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF BEIJING TIDE PHARMACEUTICAL CO LTD (CN) 2023-11-01 — — EP disclosed
EP-4015513-B1 IRAK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI MEIYUE BIOTECH DEV CO LTD (CN) 2023-11-01 — — EP disclosed
CN-111587112-B Rho-related inhibitors of coiled-coil-containing protein kinases 卡德门企业有限公司 2023-10-10 — — CN disclosed
US-20220289719-A1 HETEROCYCLIC COMPOUNDS AS MNK INHIBITORS NANJING INNOCARE PHARMA TECH CO., LTD. (CN) 2022-09-15 — — US disclosed
US-20220204473-A1 COMPOUND AS IRAK INHIBITOR WUHAN CREATERNA SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2022-06-30 — — US disclosed
EP-4015513-A1 IRAK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Meiyue Biotech Development Co., Ltd. (CN) 2022-06-22 — — EP disclosed
CN-109153665-B Novel 2-substituted indazoles, method for the production thereof, pharmaceutical preparations containing the same and use thereof for producing medicaments 拜耳医药股份有限公司 2021-10-15 — — CN disclosed
EP-3889150-A1 COMPOUND SERVING AS IRAK INHIBITOR Shanghai Meiyue Biotech Development Co., Ltd. (CN) 2021-10-06 — — EP disclosed
WO-2021057785-A1 IRAK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海美悦生物科技发展有限公司 2021-04-01 — — WO disclosed
WO-2013174744-A1 THIENOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2013-11-28 — — WO disclosed
WO-2013174743-A1 SUBSTITUTED PYRROLOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2013-11-28 — — WO disclosed
EP-2593457-A1 PYRAZOLO [1, 5A]PYRIMIDINE AND THIENO [3, 2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2013-05-22 — — EP disclosed
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 — — US disclosed
US-20120015962-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS ARORA NIDHI (US) 2012-01-19 — — US disclosed
US-20120015962-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS ARORA NIDHI (US) 2012-01-19 — — US disclosed
WO-2012007375-A1 PYRAZOLO [1, 5A] PYRIMIDINE AND THIENO [3, 2B] PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2012-01-19 — — WO disclosed
WO-2012007375-A1 PYRAZOLO [1, 5A] PYRIMIDINE AND THIENO [3, 2B] PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2012-01-19 — — WO disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 — — US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 AXL 2872/4885CHEK1 1404/4885MKNK1 1629/4885
US-20220204473-A1 COMPOUND AS IRAK INHIBITOR IRAK1, IRAK3, IRAK2 AXL 889/4885CHEK1 722/4885MKNK1 454/4885
US-20220289719-A1 HETEROCYCLIC COMPOUNDS AS MNK INHIBITORS NIM1K, MAP3K1, MAPKAPK2 AXL 1440/4885CHEK1 186/4885MKNK1 28/4885
US-20120015962-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS IRAK4, IRAK1, IRAK2 AXL 1243/4885CHEK1 524/4885MKNK1 381/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 AXL 2872/4885CHEK1 1404/4885MKNK1 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.